Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases

European Journal of Endocrinology

Volumn 166, Issue 4, 2012, Pages 717-725

  Bemelmans, Remy H H ^a   Wassink, Annemarie M J ^a   Van Der Graaf, Yolanda ^a   Nathoe, Hendrik M ^a   Vernooij, Joris W P ^a   Spiering, Wilko ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE;

ADULT; AGE; ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTING HEART RATE; RISK FACTOR; SECOND MANIFESTATION OF ARTERIAL DISEASE STUDY; SMOKING; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REST; RISK FACTORS; VASCULAR DISEASES; YOUNG ADULT;

EID: 84859387015     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1017     Document Type: Article

References (40)

1. Grassi G, Dell'Oro R, Facchini A, Quarti TF, Bolla GB & Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. Journal of Hypertension 2004 22 2363-2369. (doi:10.1097/00004872-200412000-00019)
2. Esteghamati A, Khalilzadeh O, Anvari M, Rashidi A, Mokhtari M & Nakhjavani M. Association of serum leptin levels with homeostasis model assessment-estimated insulin resistance and metabolic syndrome: the key role of central obesity. Metabolic Syndrome and Related Disorders 2009 7 447-452. (doi:10.1089/met.2008.0100)
3. Anderson EA, Hoffman RP, Balon TW, Sinkey CA & Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. Journal of Clinical Investigation 1991 87 2246-2252. (doi:10.1172/JCI115260)
4. Sauter A, Goldstein M, Engel J & Ueta K. Effect of insulin on central catecholamines. Brain Research 1983 260 330-333. (doi:10.1016/0006-8993(83) 90691-1)
5. Ward KR, Bardgett JF, Wolfgang L & Stocker SD. Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 2011 57 435-441. (doi:10.1161/ HYPERTENSIONAHA.110.160671)
6. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Choe I, Winnicki M, Palatini P, Sivitz WI & Somers VK. Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects. Journal of Hypertension 2001 19 1089-1094. (doi:10.1097/00004872-200106000-00014)
7. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA & Tepper RI. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995 83 1263-1271. (doi:10.1016/0092-8674(95)90151-5)
8. Shek EW, Brands MW & Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998 31 409-414.
9. Jamerson KA, Julius S, Gudbrandsson T, Andersson O & Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993 21 618-623. (Pubitemid 23120215)
10. Masuo K, Mikami H, Ogihara T & Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. American Journal of Hypertension 1997 10 77-83. (doi:10.1016/S0895-7061(96)00303-2)
11. Palatini P, Mos L, Santonastaso M, Zanatta N, Mormino P, Saladini F, Bortolazzi A, Cozzio S & Garavelli G. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity 2011 19 618-623. (doi:10.1038/oby.2010.191)
12. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R & Mancia G. Heart rate as marker of sympathetic activity. Journal of Hypertension 1998 16 1635-1639. (doi:10.1097/00004872-199816110-00010)
13. Ho JE, Bittner V, Demicco DA, Breazna A, Deedwania PC & Waters DD. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (data from the Treating to New Targets [TNT] trial). American Journal of Cardiology 2010 105 905-911. (doi:10.1016/j.amjcard.2009.11. 035)
14. Palatini P & Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clinical and Experimental Hypertension 2004 26 637-644. (doi:10.1081/CEH-200031959)
15. Carnethon MR, Golden SH, Folsom AR, Haskell W & Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study, 1987-1998. Circulation 2003 107 2190-2195. (doi:10.1161/01.CIR.0000066324.74807.95)
16. Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B & Daviglus ML. Resting heart rate in middle age and diabetes development in older age. Diabetes Care 2008 31 335-339. (doi:10.2337/dc07-0874)
17. Shigetoh Y, Adachi H, Yamagishi S, Enomoto M, Fukami A, Otsuka M, Kumagae S, Furuki K, Nanjo Y & Imaizumi T. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. American Journal of Hypertension 2009 22 151-155. (doi:10.1038/ajh.2008.331)
18. Zhang X, Shu XO, Xiang YB, Yang G, Li H, Cai H, Gao YT & Zheng W. Resting heart rate and risk of type 2 diabetes in women. International Journal of Epidemiology 2010 39 900-906. (doi:10.1093/ije/dyq068)
19. Nagaya T, Yoshida H, Takahashi H & Kawai M. Resting heart rate and blood pressure, independent of each other, proportionally raise the risk for type-2 diabetes mellitus. International Journal of Epidemiology 2010 39 215-222. (doi:10.1093/ije/dyp229)
20. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G & Molitch ME. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care 2006 29 914-919. (doi:10.2337/diacare.29.04.06.dc05-1729)
21. Eberly LE, Cohen JD, Prineas R & Yang L. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003 26 848-854. (doi:10.2337/diacare.26.3.848)
22. Kannel WB & McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979 2 120-126. (doi:10.2337/diacare.2.2.120)
23. Gough SC, Kragh N, Ploug UJ & Hammer M. Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009 2 179-184. (doi:10.2147/DMSOTT.S7088)
24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA & Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002 346 393-403. (doi:10.1056/NEJMoa012512)
25. Stern MP. Diabetes and cardiovascular disease. The "common soil"hypothesis. Diabetes 1995 44 369-374. (doi:10.2337/diabetes.44.4.369)
26. Grassi G, Arenare F, Pieruzzi F, Brambilla G & Mancia G. Sympathetic activation in cardiovascular and renal disease. Journal of Nephrology 2009 22 190-195.
27. Simons PC, Algra A, van de Laak MF, Grobbee DE & van der Graaf Y. Second manifestations of arterial disease (SMART) study: rationale and design. European Journal of Epidemiology 1999 15 773-781. (doi:10.1023/A:1007621514757)
28. Reaven GM, Lithell H & Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New England Journal of Medicine 1996 334 374-381. (doi:10.1056/ NEJM199602083340607)
29. Shimazu T. Innervation of the liver and glucoregulation: roles of the hypothalamus and autonomic nerves. Nutrition 1996 12 65-66. (Pubitemid 26082758)
30. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000 43 533-549. (doi:10.1007/s001250051341)
31. Deibert DC & DeFronzo RA. Epinephrine-induced insulin resistance in man. Journal of Clinical Investigation 1980 65 717-721. (doi:10.1172/JCI109718)
32. Zeman RJ, Ludemann R, Easton TG & Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. American Journal of Physiology 1988 254 E726-E732.
33. Julius S, Gudbrandsson T, Jamerson K & Andersson O. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Pressure 1992 1 9-19. (doi:10.3109/08037059209065119)
34. Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Medicine 1997 24 321-336. (doi:10.2165/00007256-199724050-00004)
35. Vazquez G, Duval S, Jacobs DR Jr & Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiologic Reviews 2007 29 115-128. (doi:10.1093/epirev/mxm008)
36. Blomqvist CG & Saltin B. Cardiovascular adaptations to physical training. Annual Review of Physiology 1983 45 169-189. (doi:10.1146/annurev.ph. 45.030183.001125)
37. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G & Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006 48 787-796. (doi:10.1161/01.HYP.0000242642.42177.49)
38. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M & Bohm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011 123 1940-1946. (doi:10.1161/CIRCULATIONAHA.110.991869)
39. Vardeny O, Uno H, Braunwald E, Rouleau JL, Gersh B, Maggioni AP, Domanski M, Pfeffer MA & Solomon SD. Opposing effects of b blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. American Journal of Cardiology 2011 107 1705-1709. (doi:10.1016/j.amjcard.2011.01.064)
40. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y & Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010 376 103-111. (doi:10.1016/S0140-6736(10)60746-5)